Expect downward pressure on ORKA stock as the market prices in dilution from this large follow-on. Monitor pricing of the offerings and any concurrent news on clinical pipeline or cash burn. The second undisclosed offering adds uncertainty.
ORKA drugs
ORKA drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 28 $73.99entry
- T+1 · 7mo ago −6.08%α −6.07% · $69.49
- T+5 · 7mo ago −10.18%α −11.87% · $66.46
- T+20 · 6mo ago −20.18%α −25.65% · $59.06
- T+60 · 4mo ago +24.27%α +20.28% · $91.95
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Oruka Therapeutics filed two preliminary prospectus supplements for a combined equity offering of at least $500 million (plus $75 million overallotment) under its $1 billion shelf registration. The company estimates $496 million cash on hand as of March 31, 2026, and intends to use proceeds for general corporate purposes including R&D and working capital. The substantial dilution from this large follow-on offering is bearish for the stock.
Key Facts
- Offering $500,000,000 of common stock and pre-funded warrants, plus underwriter option for $75,000,000 additional shares
- Second concurrent common stock offering of undisclosed amount (placeholder $[] )
- Cash, cash equivalents, and investments approximately $496 million as of March 31, 2026
- Historical net tangible book value of $471.9 million ($9.69 per share) as of December 31, 2025
- Stock price $69.03 on April 24, 2026; market cap ~$3.4B
Financial Impact
Dilution of at least 15-20% of market cap from $500M+ offering; exact dilution depends on pricing and size of second offering
Risk Factors
- Significant equity dilution diluting existing shareholders
- Potential further offerings if all of $1B shelf is utilized
- No revenue or profitability to offset dilution concerns
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (ORKA), Batch item 1 | 0001213900-26-048099 |
| Document: 0001213900-26-048099-index-headers.html | 0001213900-26-048100 |
| Document: 0001213900-26-048099-index.html | 0001213900-26-048099 |
| Document: 0001213900-26-048099.txt | 0001213900-26-048099 |
| 424B5 Filing (ORKA), Batch item 5 | 0001213900-26-048100 |
Track record
40 reports on ORKA
6 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +80.05% at T+60 after the Jun 1, 2026 report. 10 of 10 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $102.46 Now $99.24 −3.14% settles Dec 15
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $104.40 Now $99.24 −4.94% settles Dec 15
- Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $106.15 Now $99.24 −6.51% settles Dec 15
- Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $104.89 Now $99.24 −5.39% settles Dec 15
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $105.35 Now $99.24 −5.80% settles Dec 14
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $105.35 Now $99.24 −5.80% settles Dec 14
- Nov 9, 20267d ago Press Release Neutral 5/10 Entry $109.50 Now $99.24 −9.37% settles Dec 9
- Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $99.55 Now $99.24 −0.31% settles Dec 2
- Nov 2, 202614d ago 144 Neutral 3/10 Entry $99.55 Now $99.24 −0.31% settles Dec 2
- Oct 26, 202621d ago 8-K Bullish 6/10 Entry $90.33 Now $99.24 +9.86% settles Nov 23
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers